Pressmeddelande -
Scandinavian Biopharma extends its agreement with USAMMDA and obtains additional financial support
In 2020, Scandinavian Biopharma entered into an agreement with the United States Army Medical Materiel Development Activity (USAMMDA) to fund manufacturing and development activities for its ETEC diarrhoea vaccine, ETVAX®. The agreement has now been extended, providing additional financial support.
The objective of USAMMDA's financial support is to accelerate the development and approval of the vaccine in the United States and to provide its personnel stationed overseas with a registered, safe and effective vaccine against ETEC, which is the most common cause of diarrhoea in travellers to subtropical/tropical regions.
"We are very proud to have received additional funding from USAMMDA for the development of our world-leading ETEC vaccine candidate. This is a confirmation that we have a very promising candidate and a well-developed plan for our remaining development program", says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
